文献速递腹部介入技术与安全SPECTCT

177Lu-DOTATATE肝动脉与静脉给药在肝优势转移性神经内分泌肿瘤中的剂量学分析

Dosimetric analyses of intra-arterial versus standard intravenous administration of 177Lu-DOTATATE in patients of well differentiated neuroendocrine tumor with liver-dominant metastatic disease.
PubMed 文献 · Br J Radiol · 2021-08-06

本研究前瞻性纳入29例Grade I-II不可手术转移性胃肠胰神经内分泌肿瘤患者,比较经肝动脉(IA)与标准静脉(IV)给予单剂177Lu-DOTATATE后的剂量学差异。IA组(15例)肝及肿瘤病灶单位活度平均剂量与IV组(14例)有显著差异(p<0.05),脾和肾则无显著差异(p>0.05)。96小时平均肿瘤/非肿瘤浓度比IA组为76.83±7.9(范围10.2-251.3),IV组为25.6±5.9(范围12-55),肿瘤浓度平均增加约3倍。

要点

  • IA给药后肝转移灶的肿瘤浓度与吸收剂量均高于标准IV给药。
  • 96小时肿瘤/非肿瘤浓度比IA组明显高于IV组。
  • 脾和肾的吸收剂量在两种给药途径间未见显著差异。

核心结论

  • 肝动脉给予177Lu-DOTATATE可使GEPNET肝转移灶获得更高的浓度和吸收剂量,可能提高PRRT疗效。

研究设计与样本

  • 前瞻性研究纳入29例Grade I-II不可手术转移性胃肠胰神经内分泌肿瘤患者。
  • IA组15例经选择性肝动脉插管给予单剂177Lu-DOTATATE,IV组14例经标准静脉给予单剂。
  • 给药后2、24、96小时行全身γ显像(前后位平面采集)及腹部SPECT/CT,用HERMES软件计算剂量。

诊断标准与关键数值

  • IA组肝及肿瘤病灶单位活度平均剂量与IV组差异显著(p<0.05),脾和肾差异不显著(p>0.05)。
  • 96小时平均肿瘤/非肿瘤浓度比IA组为76.83±7.9(范围10.2-251.3),IV组为25.6±5.9(范围12-55)。
  • 肿瘤浓度较标准静脉组平均增加约3倍。

临床应用与阅片要点

  • 对肝优势转移性GEPNET行177Lu-DOTATATE治疗时,可考虑经肝动脉给药以提高肝转移灶剂量。
  • 剂量学评估需结合全身平面显像与腹部SPECT/CT,关注肝、脾、肾及肿瘤病灶的吸收剂量。

局限性

  • 单次给药剂量学分析,样本量有限(29例),未报告长期疗效或安全性终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: The aim of the present study was to perform calculation of the absorbed doses to organs at risk and to neuroendocrine tumors and to determine whether hepatic intra-arterial (IA) injection of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) would achieve higher intratumoral concentrations than standard intravenous administration of 177Lu-DOTATATE.

METHODS: 29 patients with Grade I-II, inoperable, metastatic gastro-entero-pancreatic neuroendocrine tumor (GEPNET) were prospectively identified and enrolled for the study. 15 patients of GEPNETs with liver-dominant metastatic disease and less than 3 sites of extrahepatic metastatic disease were administered a single dose of 177Lu-DOTATATE therapy through the selective catheterization of the hepatic artery (IA group). The other 14 patients received a single dose of 177 Lu- DOTATATE through standard intravenous route (IV group). For dosimetry, whole-body γ (anterior and posterior planar acquisitions) and SPECT/CT scans of the abdomen at 2, 24 and 96 h post 177Lu-DOTATATE administration were acquired. Dosimetric calculations were done using the HERMES software.

RESULTS: The mean dose per unit activity (DpA) in the liver and tumor lesions in the IA group differed significantly (p < 0.05) but differed insignificantly in spleen and kidneys (p > 05) with the IV group. The mean tumor/non-tumor concentration at 96 h was 76.83 ± 7.9 (range 10.2-251.3) in the IA group whereas it was 25.6 ± 5.9 (Range: 12-55) in the IV group. There was an average threefold increase in tumoral concentration over the standard intravenous group.

CONCLUSION: IA administration of 177Lu-DOTATATE results in higher concentration and absorbed dose in hepatic metastases in patients of GEPNETs as compared to a single dose of PRRT administered through standard IV route, and thus seems to be a powerful tool to improve the efficacy of PRRT.

ADVANCES IN KNOWLEDGE: Measurement of the dose received by the tumor lesions and the critical organs is of paramount importance for the prognostication of a radionuclide therapy. Scant data exist on the dosimetric impact of IA administration of the therapy with 177Lu-DOTATATE on the tumors and other organs, and this study would add an impact towards the better treatment outcome in patients of neuroendocrine tumor with liver-dominant metastatic disease.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Thakral P, Sen I, Das SS, et al. Dosimetric analyses of intra-arterial versus standard intravenous administration of 177Lu-DOTATATE in patients of well differentiated neuroendocrine tumor with liver-dominant metastatic disease. Br J Radiol. 2021. PMID: 34357794. doi:10.1259/bjr.20210403

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。